Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome
Conditions
Brief summary
This is an open label, multi-cohort, and multi-center phase II study, which evaluates the clinical activity and safety of IPH4102 in Sezary Syndrome and Mycosis fungoides as single agent.
Interventions
BIOLOGICALIPH4102
Patients will receive a flat dose of 750mg
Sponsors
Innate Pharma
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
SS patients (Cohort 1): 1. Relapsed and/or refractory stage IVA, IVB SS who have received at least two prior systemic therapies; 2. Prior treatment with mogamulizumab; 3. Patients should have blood stage B2 at screening based on central evaluation by flow cytometry; 4. Feasibility of obtaining at least one skin biopsy at screening; MF patients (Cohorts 2 and All comers): 5. Relapsed and/or refractory stage IB, IIA, IIB, III, IV MF; 6. Only for Cohort 2: KIR3DL2 expression in at least one expressing skin lesion based on central evaluation by IHC; 7. Patients should have received at least two prior systemic therapies; 8. Feasibility of obtaining at least one skin biopsy at screening; Additional inclusion criteria applicable to all cohorts: 9. Male or Female, at least 18 years of age; 10. ECOG performance status ≤2; 11. The patient must have a minimum wash-out period of 3 weeks between the last dose of prior systemic therapy and the first dose of IPH4102; 12. Patients should have recovered from all non-hematological adverse events related to prior therapy to ≤ grade 1 except for alopecia; 13. Adequate baseline laboratory data: Hematology: * Hemoglobin \>9 g/dL, * Absolute neutrophil count (ANC) ≥1,500/µL, * Platelets ≥100,000/µL, Biochemistry: * Bilirubin ≤1.5 X upper limit of normal (ULN) or ≤3 X ULN for patients with Gilbert's disease, * Serum creatinine ≤1.5 X ULN, * Creatinine clearance ≥30 mL/min, calculated with the Cockcroft \& Gault formula, * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤2.5 X ULN; 14. Women of childbearing potential (WOCBP): Premenopausal females who had at least one menstrual cycle in the past 12 months and capable to become pregnant. They must have a negative serum beta-HCG pregnancy test result within seven days from start of treatment; 15. Women of childbearing potential and all men (and their female partners of childbearing potential) who are sexually active must agree to use adequate method of contraception at study entry, during treatment and for at least 9 months (270 days) following the last dose of study drug; 16. Signed informed consent form prior to any protocol-specific procedures
Exclusion criteria
1. Patients with evidence of large cell transformation (LCT) based on central histologic evaluation at screening; 2. Receipt of live vaccines within 4 weeks prior to treatment; 3. Central nervous system (CNS) lymphoma involvement; 4. Prior administration of IPH4102; 5. Concurrent enrollment in another clinical trial, unless it is an observational (non - interventional) clinical study or the follow-up period of an interventional study; 6. Autologous stem cell transplantation less than 3 months prior to enrollment; 7. Prior allogenic transplantation; 8. Patients who have undergone major surgery ≤ 4 weeks prior to study entry; 9. Patients with known NCI CTCAE grade 3 or higher active systemic or cutaneous viral, bacterial, or fungal infection; 10. Patients who have Hepatitis B Virus infection determined as HBsAg positive and / or Hepatitis C Virus infection determined as detection of HCV RNA in serum or plasma by a sensitive quantitative molecular method; 11. Known or tested positive for human immunodeficiency virus (HIV); 12. Patients with a history of other malignancies during the past five years apart from the disease subject of this study. The following are exempt from the five-year limit: non-melanoma skin cancer, lymphomatoid papulosis, resected thyroid cancer, biopsy-proven cervical intraepithelial neoplasia, Ductal carcinoma in situ (DCIS) or cervical carcinoma in situ 13. Pregnant or breastfeeding women; 14. Known clinically significant cardiovascular disease or condition, including: * Class III or IV cardiovascular disease according to the New York Heart Association (NYHA) Functional Classification; * Any uncontrolled arrhythmia (per the investigator's discretion); * Uncontrolled hypertension (per the investigator's discretion). 15. Patients with autoimmune disease on systemic immunosuppressive treatment; 16. Patients with any serious underlying medical condition that would impair their ability to receive or tolerate the planned treatment and/or comply with study protocol; 17. Patients with dementia or altered mental status that would preclude understanding and rendering of informed consent document.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate (ORR) | From the first dose until study completion, an expected average of 2 years | Using the Olsen (2011, JCO) criteria (All cohorts) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Treatment-Emergent Adverse Events (Safety and tolerability) (All cohorts) | From first dose until study completion, an expected average of 2 years | patients with treatment-related adverse events as assessed by CTCAE v5.0 |
| Quality of life (QoL) (All cohorts) | Through study completion, an expected average of 2 years | Using the Skindex29 questionnaire to assesse the effects of skin disease on quality of life in three domains: Symptoms, Emotions, and Functioning |
| pruritus (All cohorts) | Through study completion, an expected average of 2 years | Using Visual Analog Scale (VAS) for prutitus assessment: From 0 = No pruritus to 10 = Pruritus as bad as it could possibly be |
| ORR using blinded central review (Cohort 1) | From the first dose until study completion, an expected average of 2 years | Using the Olsen (2011, JCO) criteria |
| Progression free survival (PFS) (All cohorts) | From the first dose until study completion, an expected average of 2 years | Will be evaluated using the Kaplan-Meier method |
| Overall survival (OS) (All cohorts) | From the first dose until study completion, an expected average of 2 years | Will be evaluated using the Kaplan-Meier method |
| PK parameters : Maximum Plasma Concentration of IPH4102 alone (All cohorts) | From the first dose until study completion, an expected average of 2 years | Maximum Plasma Concentration (Cmax) (W1, W5) |
| PK parameters :Trough Concentration of IPH4102 alone (All cohorts) | From the first dose until study completion, an expected average of 2 years | Trough Concentration (Ctrough) every 8 or 12 weeks |
| Immunogenicity of IPH4102 alone (All cohorts) | From the first dose until study completion, an expected average of 2 years | A serum sample will be collected at the specified time points for evaluation of anti-drug antibodies (ADA). |
| Duration of Response (DOR) | From the first dose until study completion, an expected average of 2 years | Will be summarized descriptively by using the Kaplan-Meier estimator |
Countries
Austria, Belgium, France, Germany, Italy, Poland, Spain, United States
Outcome results
None listed